[B01AD01, streptokinase, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Moroctocog alfa.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Moroctocog alfa.]
[B01AD04, urokinase, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Ticagrelor.]
[B01AA03, warfarin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Moroctocog alfa.]
[B01AE03, argatroban, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Anistreplase.]
[B05AA05, dextran, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Moroctocog alfa.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Moroctocog alfa.]
[B05CB02, sodium citrate, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Moroctocog alfa.]
[B01AB07, parnaparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Phenprocoumon.]
[B01AC13, abciximab, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Moroctocog alfa.]
[B01AD01, streptokinase, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Antihemophilic factor, human recombinant.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.]
[B01AD04, urokinase, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ticagrelor.]
[B01AA03, warfarin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.]
[B01AE03, argatroban, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Anistreplase.]
[B05AA05, dextran, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Antihemophilic factor, human recombinant.]
[B05CB02, sodium citrate, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Antihemophilic factor, human recombinant.]
[B01AB07, parnaparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Phenprocoumon.]
[B01AC13, abciximab, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor, human recombinant.]
[B01AD01, streptokinase, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Susoctocog alfa.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Susoctocog alfa.]
[B01AD04, urokinase, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Ticagrelor.]
[B01AA03, warfarin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Susoctocog alfa.]
[B01AE03, argatroban, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Anistreplase.]
[B05AA05, dextran, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Susoctocog alfa.]
[B05CB02, sodium citrate, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Susoctocog alfa.]
[B01AB07, parnaparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Phenprocoumon.]
[B01AC13, abciximab, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Susoctocog alfa.]
[B01AD01, streptokinase, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Turoctocog alfa.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Turoctocog alfa.]
[B01AD04, urokinase, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Ticagrelor.]
[B01AA03, warfarin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Turoctocog alfa.]
[B01AE03, argatroban, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Anistreplase.]
[B05AA05, dextran, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Turoctocog alfa.]
[B05CB02, sodium citrate, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Turoctocog alfa.]
[B01AB07, parnaparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Phenprocoumon.]
[B01AC13, abciximab, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Turoctocog alfa.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Levobupivacaine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01XX27, arsenic trioxide, Arsenic trioxide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A06AH05, naldemedine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[P01CA02, benznidazole, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07XX13, valbenazine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[J01MA23, delafloxacin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Betrixaban.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Antihemophilic factor (recombinant), PEGylated.]
[L04AA37, baricitinib, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01GB14, plazomicin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N03AX17, stiripentol, Stiripentol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Antihemophilic factor (recombinant), PEGylated.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[D08AE05, chloroxylenol, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC23, cilostazol, Cilostazol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BA14, solriamfetol, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07XX11, pitolisant, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M09AX08, golodirsen, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Dienogest may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C08CA16, clevidipine, Clevidipine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AE02, lepirudin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Lepirudin.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BA03, choline salicylate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AX25, chondroitin sulfates, Chondroitin sulfate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Peginterferon alfa-2b.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01XA01, cisplatin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AD11, tenecteplase, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Tenecteplase.]
[N01BB10, levobupivacaine, Levobupivacaine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AA04, clomipramine, Clomipramine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH02, clozapine, Clozapine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01GB12, arbekacin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01XB01, colistin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A04AA03, tropisetron, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C05BB03, invert sugar, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V08AB05, iopromide, Iopromide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V08AB07, ioversol, Ioversol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V08AB12, ioxilan, Ioxilan may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[H01AX01, pegvisomant, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegvisomant.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AB12, bemiparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N03AX09, lamotrigine, Lamotrigine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Melperone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AX06, nefazodone, Nefazodone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01DX16, nicorandil, Nicorandil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AX05, fondaparinux, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Fondaparinux.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AA01, desipramine, Desipramine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V04CH02, indigo carmine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R05DA08, pholcodine, Pholcodine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AA13, pegfilgrastim, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegfilgrastim.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[D07XC04, diflucortolone, Difluocortolone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01AA05, digoxin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX24, pegaspargase, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegaspargase.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[H03BC01, potassium perchlorate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC07, dipyridamole, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Drotrecogin alfa.]
[S01AX06, resorcinol, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AA12, doxepin, Doxepin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A12CA02, sodium sulfate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC18, triflusal, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Troxerutin.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD03, anistreplase, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Anistreplase.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L03AX05, pidotimod, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Sodium aurothiomalate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B05AA05, dextran, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Dextran.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AD05, plasmin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Fibrinolysin.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01BC03, tegafur, Tegafur may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01CB04, aurothioglucose, Aurothioglucose may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01LA03, pegaptanib, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegaptanib.]
[B01AA12, fluindione, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Fluindione.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05AD01, haloperidol, Haloperidol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05AH04, quetiapine, Quetiapine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01XA14, heparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Heparin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G04BD06, propiverine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Hydroxyethyl Starch may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B05XA08, sodium acetate, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Sodium citrate.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R01AD07, tixocortol, Tixocortol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A11HA07, inositol, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Milnacipran may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegademase.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AX05, inosine pranobex, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AE06, bivalirudin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Bivalirudin.]
[S01AA24, kanamycin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC22, prasugrel, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Prasugrel.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA21, amikacin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B05XA11, magnesium chloride, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Dalteparin.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Paliperidone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Methimazole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01BA04, pemetrexed, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V04CG05, methylene blue, Methylene blue may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A03FA01, metoclopramide, Metoclopramide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AB07, parnaparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Parnaparin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AB10, tinzaparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AA09, amitriptyline, Amitriptyline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Certolizumab pegol.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C07AA12, nadolol, Nadolol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.]
[S03AA01, neomycin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01AA23, netilmicin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Desvenlafaxine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AB08, reviparin, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Reviparin.]
[N02AA02, opium, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Ancrod.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AB09, danaparoid, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Danaparoid.]
[J04AB30, capreomycin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G04BD11, fesoterodine, Fesoterodine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C07AA23, penbutolol, Penbutolol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[L01XX08, pentostatin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AA02, phenindione, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Phenprocoumon.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N06BX03, piracetam, Piracetam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC13, abciximab, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Alteplase.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Polyethylene glycol.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01BA02, procainamide, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[R06AD02, promethazine, Promethazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B01AC09, epoprostenol, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Epoprostenol.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[P02CC01, pyrantel, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C01BA01, quinidine, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C05BB02, polidocanol, The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Polidocanol.]
[J01GB08, sisomicin, Antihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sodium fluoride may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor (recombinant), PEGylated.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD01, streptokinase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Antihemophilic factor human.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Antihemophilic factor human.]
[B01AD04, urokinase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Ticagrelor.]
[B01AA03, warfarin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Antihemophilic factor human.]
[B01AE03, argatroban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Anistreplase.]
[B05AA05, dextran, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Antihemophilic factor human.]
[B05CB02, sodium citrate, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Antihemophilic factor human.]
[B01AB07, parnaparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Phenprocoumon.]
[B01AC13, abciximab, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor human.]
[B01AD01, streptokinase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Streptokinase.]
[B01AE07, dabigatran etexilate, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dabigatran etexilate.]
[B02AB01, aprotinin, Aprotinin may increase the thrombogenic activities of Antihemophilic factor human.]
[B02AA02, tranexamic acid, Tranexamic acid may increase the thrombogenic activities of Antihemophilic factor human.]
[B01AD04, urokinase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Urokinase.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Rivaroxaban.]
[B01AC24, ticagrelor, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Ticagrelor.]
[B01AA03, warfarin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Warfarin.]
[B01AE01, desirudin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.]
[B01AX01, defibrotide, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Defibrotide.]
[B01AF02, apixaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Apixaban.]
[B02AA03, 4-aminomethylbenzoic acid, Aminomethylbenzoic acid may increase the thrombogenic activities of Antihemophilic factor human.]
[B01AE03, argatroban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Argatroban.]
[B01AC26, vorapaxar, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Vorapaxar.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Acenocoumarol.]
[B01AA01, dicumarol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dicoumarol.]
[B01AF03, edoxaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Edoxaban.]
[B01AA11, tioclomarol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tioclomarol.]
[B01AC25, cangrelor, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Cangrelor.]
[B01AF04, betrixaban, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Betrixaban.]
[B01AE02, lepirudin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.]
[B01AD11, tenecteplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tenecteplase.]
[B01AB12, bemiparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Bemiparin.]
[B01AX05, fondaparinux, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fondaparinux.]
[B01AC07, dipyridamole, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dipyridamole.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Drotrecogin alfa.]
[B01AC18, triflusal, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Triflusal.]
[C05CA04, troxerutin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Troxerutin.]
[B01AD03, anistreplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Anistreplase.]
[B01AC13, abciximab, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Abciximab.]
[S01XA13, alteplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Alteplase.]
[B01AC09, epoprostenol, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Epoprostenol.]
[B02AA01, 6-aminocaproic acid, The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor human.]
[B05AA05, dextran, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dextran.]
[B01AD05, plasmin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fibrinolysin.]
[B01AA12, fluindione, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fluindione.]
[S01XA14, heparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Heparin.]
[B02AB02, alpha 1-antitrypsin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human.]
[S02AA06, hydrogen peroxide, Hydrogen peroxide may increase the thrombogenic activities of Antihemophilic factor human.]
[B05CB02, sodium citrate, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Sodium citrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Bivalirudin.]
[B01AC22, prasugrel, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Prasugrel.]
[B01AB06, nadroparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Nadroparin.]
[B01AB05, enoxaparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Enoxaparin.]
[B01AB04, dalteparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dalteparin.]
[B02BA02, vitamin K3, Menadione may increase the thrombogenic activities of Antihemophilic factor human.]
[B01AB07, parnaparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Parnaparin.]
[B01AB10, tinzaparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tinzaparin.]
[B01AB08, reviparin, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reviparin.]
[B01AD07, reteplase, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reteplase.]
[B01AD09, ancrod, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Ancrod.]
[B01AB09, danaparoid, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Danaparoid.]
[B01AA02, phenindione, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Phenindione.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Phenprocoumon.]
